Posos builds the first drug database using AI and gets approval from the French National Authority for Health

Posos Medical Database, the first AI-built drug database, approved by French Health Authorities

The company received approval of its AI-designed drug database by the French National Authority for Health (HAS). While no French company has been awarded this approval for over 20 years, Posos has developed an advanced database in just two years through its AI models. Presented in a knowledge graph format, the Posos Medical Database seamlessly integrates multiple sources of specialized medical information, ensuring comprehensive responses and enabling nuanced pharmaceutical analysis. Unlike older databases designed for information display, this new-generation solution was built to assimilate all patient record data, facilitating personalized medication management recommendations. These proprietary algorithms now support the integration of new countries and languages every six months, enabling international publishers to roll out their software in several countries with consistent functionality. Posos is internationally recognized for its expertise in artificial intelligence, with its responsible AI algorithms earning accolades at the American Association for Computational Linguistics congress last summer.

An architecture built for international EHR and EMR softwares

This marks the first step in Posos' international expansion and a major milestone in fulfilling our mission to help healthcare professionals around the world provide better care by delivering precise medical knowledge tailored to each patient. Physician burnout has been on the rise as the complexity of healthcare and administrative burden of electronic medical records has created a difficult environment for clinicians. The platform provides a powerful solution to empower physicians as they navigate an increasingly complex patient medication system. These advances position Posos as a leader in accurate data architecture, not only minimizing irrelevant alerts but also facilitating the prescription of the most effective therapeutic solutions for each patient, regardless of their current treatments, chronic conditions, and medical history.

A groundbreaking innovation in healthcare

In the United States, medication errors are reported to cause complications in 1.3 million people each year, contributing to a significant number of preventable deaths. Through its database, Posos is accelerating its mission to help healthcare professionals deliver better care by offering healthcare providers a prescription assistance solution that helps to quickly find the perfect medication dosage while minimizing side effects. The company expects to secure strategic partnerships and begin offering its platform to US clinicians later in 2024.

Emmanuel Bilbault, CEO of Posos, says: “This approval is recognition of a groundbreaking innovation in healthcare, ushering in a new era of drug databases, offering a prescription assistance experience that was previously impossible. Our goal is to quickly become the world's leading knowledge base on medicines, that is easy to integrate into each country's software, so that we can offer each patient a truly personalized approach to drug management, whatever the prescriber's language.”

About Posos 

Founded in 2018, Posos is a MedTech company that has built the world's most advanced artificial intelligence platform dedicated to medical prescription. Its AI models seamlessly integrate into leading hospital software in Europe, enabling healthcare providers to prescribe in real-time based on the latest recommendations. Co-created by Posos' pharmacists and engineers, this platform, whose development was accelerated for the first time by AI, has received approval from health authorities in France. Posos is committed to assisting healthcare professionals by delivering the most suitable medical knowledge for each patient. Learn more: https://www.posos.co/ 

‍

About HAS approval of drug databases

In accordance with article L. 161-38 of the French Social Security Code, the HAS is responsible for approving drug databases (BdM) for use with certified prescription assistance software (LAP) and dispensation assistance software (LAD), based on a quality charter it has drawn up. The purpose of the charter is to define specific features that contribute to essential aspects of the quality of drug databases. It targets criteria deemed critical for healthcare software. 

Learn more: https://www.has-sante.fr/jcms/c_672761/fr/agrement-des-bases-de-donnees-sur-les-medicaments

‍